Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Fragile X disappointments upset autism ambitions.

Literature DB >> 25722228

Fragile X disappointments upset autism ambitions.

Asher Mullard.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2015 PMID： 25722228 DOI： 10.1038/nrd4555

Source DB: PubMed Journal: Nat Rev Drug Discov ISSN： 1474-1776 Impact factor: 84.694

× No keyword cloud information.

1 in total

Review 1. Drug discovery for autism spectrum disorder: challenges and opportunities.

Authors: Anirvan Ghosh; Aubin Michalon; Lothar Lindemann; Paulo Fontoura; Luca Santarelli
Journal: Nat Rev Drug Discov Date: 2013-10 Impact factor: 84.694

1 in total

19 in total

Review 1. Altered Neuronal and Circuit Excitability in Fragile X Syndrome.

Authors: Anis Contractor; Vitaly A Klyachko; Carlos Portera-Cailliau
Journal: Neuron Date: 2015-08-19 Impact factor: 17.173

Review 2. Unifying Views of Autism Spectrum Disorders: A Consideration of Autoregulatory Feedback Loops.

Authors: Caitlin Mullins; Gord Fishell; Richard W Tsien
Journal: Neuron Date: 2016-03-16 Impact factor: 17.173

3. Selective inhibition of glycogen synthase kinase 3α corrects pathophysiology in a mouse model of fragile X syndrome.

Authors: Patrick K McCamphill; Laura J Stoppel; Rebecca K Senter; Michael C Lewis; Arnold J Heynen; David C Stoppel; Vinay Sridhar; Katie A Collins; Xi Shi; Jen Q Pan; Jon Madison; Jeffrey R Cottrell; Kimberly M Huber; Edward M Scolnick; Edward B Holson; Florence F Wagner; Mark F Bear
Journal: Sci Transl Med Date: 2020-05-20 Impact factor: 17.956

4. Tactile Defensiveness and Impaired Adaptation of Neuronal Activity in the Fmr1 Knock-Out Mouse Model of Autism.

Authors: Cynthia X He; Daniel A Cantu; Shilpa S Mantri; William A Zeiger; Anubhuti Goel; Carlos Portera-Cailliau
Journal: J Neurosci Date: 2017-06-12 Impact factor: 6.167

Review 5. Therapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and Back.

Authors: Christina Gross; Anne Hoffmann; Gary J Bassell; Elizabeth M Berry-Kravis
Journal: Neurotherapeutics Date: 2015-07 Impact factor: 7.620

Review 6. Central Nervous System Trial Failures: Using the Fragile X Syndrome-mGluR5 Drug Target to Highlight the Complexities of Translating Preclinical Discoveries Into Human Trials.

Authors: Margaret C Grabb; William Z Potter
Journal: J Clin Psychopharmacol Date: 2022 May-Jun 01 Impact factor: 3.118

Fragile X disappointments upset autism ambitions.

Review 1. Drug discovery for autism spectrum disorder: challenges and opportunities.

Review 1. Altered Neuronal and Circuit Excitability in Fragile X Syndrome.

Review 2. Unifying Views of Autism Spectrum Disorders: A Consideration of Autoregulatory Feedback Loops.

3. Selective inhibition of glycogen synthase kinase 3α corrects pathophysiology in a mouse model of fragile X syndrome.

4. Tactile Defensiveness and Impaired Adaptation of Neuronal Activity in the Fmr1 Knock-Out Mouse Model of Autism.

Review 5. Therapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and Back.

Review 6. Central Nervous System Trial Failures: Using the Fragile X Syndrome-mGluR5 Drug Target to Highlight the Complexities of Translating Preclinical Discoveries Into Human Trials.

7. MDM2 inhibition rescues neurogenic and cognitive deficits in a mouse model of fragile X syndrome.

Review 8. Updated report on tools to measure outcomes of clinical trials in fragile X syndrome.

9. Reversal of behavioural phenotype by the cannabinoid-like compound VSN16R in fragile X syndrome mice.

Review 10. Novel roles of amyloid-beta precursor protein metabolites in fragile X syndrome and autism.